{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T18:34:40Z","timestamp":1792607680420,"version":"4.5.0"},"reference-count":83,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["Intramural Program of NIAAA"],"award-info":[{"award-number":["Intramural Program of NIAAA"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hepatol Int"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1007\/s12072-020-10082-6","type":"journal-article","created":{"date-parts":[[2020,9,5]],"date-time":"2020-09-05T16:02:27Z","timestamp":1599321747000},"page":"667-676","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":35,"title":["Interleukin-22 in alcoholic hepatitis and beyond"],"prefix":"10.1007","volume":"14","author":[{"given":"Xiaogang","family":"Xiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seonghwan","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dechun","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay H.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,5]]},"reference":[{"issue":"5","key":"10082_CR1","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1053\/j.gastro.2011.09.002","volume":"141","author":"B Gao","year":"2011","unstructured":"Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new therapeutic targets. Gastroenterology. 2011;141(5):1572\u201385.","journal-title":"Gastroenterology"},{"issue":"5","key":"10082_CR2","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/hep.30369","volume":"69","author":"G Szabo","year":"2019","unstructured":"Szabo G, et al. Alcohol-related liver disease: areas of consensus, unmet needs and opportunities for further study. Hepatology. 2019;69(5):2271\u201383.","journal-title":"Hepatology"},{"issue":"4","key":"10082_CR3","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/gutjnl-2019-319720","volume":"69","author":"MA Avila","year":"2020","unstructured":"Avila MA, et al. Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting. Gut. 2020;69(4):764\u201380.","journal-title":"Gut"},{"issue":"1","key":"10082_CR4","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.30866","volume":"71","author":"DW Crabb","year":"2020","unstructured":"Crabb DW, et al. Diagnosis and treatment of alcohol-associated liver diseases: 2019 practice guidance from the american association for the study of liver diseases. Hepatology. 2020;71(1):306\u201333.","journal-title":"Hepatology"},{"issue":"26","key":"10082_CR5","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1056\/NEJMra0805786","volume":"360","author":"MR Lucey","year":"2009","unstructured":"Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl J Med. 2009;360(26):2758\u201369.","journal-title":"N Engl J Med"},{"issue":"4","key":"10082_CR6","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1016\/j.jhep.2010.07.016","volume":"54","author":"TD Sandahl","year":"2011","unstructured":"Sandahl TD, et al. Incidence and mortality of alcoholic hepatitis in Denmark 1999\u20132008: a nationwide population based cohort study. J Hepatol. 2011;54(4):760\u20134.","journal-title":"J Hepatol"},{"issue":"11","key":"10082_CR7","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.cgh.2019.01.026","volume":"17","author":"ND Shah","year":"2019","unstructured":"Shah ND, et al. Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. Clin Gastroenterol Hepatol. 2019;17(11):2320\u20139 (e12).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10082_CR8","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1053\/j.gastro.2016.02.042","volume":"150","author":"DW Crabb","year":"2016","unstructured":"Crabb DW, et al. Standard definitions and common data elements for clinical trials in patients with alcoholic hepatitis: recommendation from the NIAAA alcoholic hepatitis consortia. Gastroenterology. 2016;150(4):785\u201390.","journal-title":"Gastroenterology"},{"issue":"2","key":"10082_CR9","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jhep.2018.12.008","volume":"70","author":"T Gustot","year":"2019","unstructured":"Gustot T, Jalan R. Acute-on-chronic liver failure in patients with alcohol-related liver disease. J Hepatol. 2019;70(2):319\u201327.","journal-title":"J Hepatol"},{"issue":"4","key":"10082_CR10","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/hep.30056","volume":"68","author":"JS Bajaj","year":"2018","unstructured":"Bajaj JS, et al. Acute-on-chronic liver failure: getting ready for prime time? Hepatology. 2018;68(4):1621\u201332.","journal-title":"Hepatology"},{"issue":"4","key":"10082_CR11","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.cgh.2013.06.013","volume":"12","author":"AK Singal","year":"2014","unstructured":"Singal AK, et al. Alcoholic hepatitis: current challenges and future directions. Clin Gastroenterol Hepatol. 2014;12(4):555\u201364 (quiz e31\u20132).","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10082_CR12","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1053\/j.gastro.2016.02.074","volume":"150","author":"M Thursz","year":"2016","unstructured":"Thursz M, Morgan TR. Treatment of severe alcoholic hepatitis. Gastroenterology. 2016;150(8):1823\u201334.","journal-title":"Gastroenterology"},{"issue":"2","key":"10082_CR13","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1136\/gut.2010.224097","volume":"60","author":"P Mathurin","year":"2011","unstructured":"Mathurin P, et al. Corticosteroids improve short-term survival in patients with severe alcoholic hepatitis: meta-analysis of individual patient data. Gut. 2011;60(2):255\u201360.","journal-title":"Gut"},{"issue":"2","key":"10082_CR14","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/ajg.2017.469","volume":"113","author":"AK Singal","year":"2018","unstructured":"Singal AK, et al. ACG clinical guideline: alcoholic liver disease. Am J Gastroenterol. 2018;113(2):175\u201394.","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10082_CR15","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1001\/jamainternmed.2018.6536","volume":"179","author":"BP Lee","year":"2019","unstructured":"Lee BP, et al. National trends and long-term outcomes of liver transplant for alcohol-associated liver disease in the United States. JAMA Intern Med. 2019;179(3):340\u20138.","journal-title":"JAMA Intern Med"},{"issue":"2 Pt 1","key":"10082_CR16","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/0016-5085(78)90790-4","volume":"74","author":"HR Lesesne","year":"1978","unstructured":"Lesesne HR, Bozymski EM, Fallon HJ. Treatment of alcoholic hepatitis with encephalopathy. Comparison of prednisolone with caloric supplements. Gastroenterology. 1978;74(2 Pt 1):169\u201373.","journal-title":"Gastroenterology"},{"issue":"5","key":"10082_CR17","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/S2468-1253(19)30326-7","volume":"5","author":"TS Sehrawat","year":"2020","unstructured":"Sehrawat TS, Liu M, Shah VH. The knowns and unknowns of treatment for alcoholic hepatitis. Lancet Gastroenterol Hepatol. 2020;5(5):494\u2013506.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"2","key":"10082_CR18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1053\/j.gastro.2018.05.011","volume":"155","author":"A Louvet","year":"2018","unstructured":"Louvet A, et al. Corticosteroids reduce risk of death within 28 days for patients with severe alcoholic hepatitis, compared with pentoxifylline or placebo-a meta-analysis of individual data from controlled trials. Gastroenterology. 2018;155(2):458\u201368 (e8).","journal-title":"Gastroenterology"},{"issue":"1","key":"10082_CR19","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-018-0014-7","volume":"4","author":"HK Seitz","year":"2018","unstructured":"Seitz HK, et al. Alcoholic liver disease. Nat Rev Dis Primers. 2018;4(1):16.","journal-title":"Nat Rev Dis Primers"},{"issue":"2","key":"10082_CR20","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jhep.2018.10.023","volume":"70","author":"B Gao","year":"2019","unstructured":"Gao B, et al. Inflammatory pathways in alcoholic steatohepatitis. J Hepatol. 2019;70(2):249\u201359.","journal-title":"J Hepatol"},{"issue":"4","key":"10082_CR21","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1002\/hep.28530","volume":"64","author":"P Mandrekar","year":"2016","unstructured":"Mandrekar P, et al. Alcoholic hepatitis: Translational approaches to develop targeted therapies. Hepatology. 2016;64(4):1343\u201355.","journal-title":"Hepatology"},{"issue":"1","key":"10082_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.alcohol.2004.07.008","volume":"34","author":"CS Lieber","year":"2004","unstructured":"Lieber CS. Alcoholic fatty liver: its pathogenesis and mechanism of progression to inflammation and fibrosis. Alcohol. 2004;34(1):9\u201319.","journal-title":"Alcohol"},{"issue":"8","key":"10082_CR23","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1053\/j.gastro.2016.01.025","volume":"150","author":"B Gao","year":"2016","unstructured":"Gao B, Tsukamoto H. Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe? Gastroenterology. 2016;150(8):1704\u20139.","journal-title":"Gastroenterology"},{"issue":"6","key":"10082_CR24","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1053\/j.gastro.2014.01.020","volume":"146","author":"B Schnabl","year":"2014","unstructured":"Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014;146(6):1513\u201324.","journal-title":"Gastroenterology"},{"issue":"5","key":"10082_CR25","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1053\/j.gastro.2012.09.008","volume":"143","author":"P Kubes","year":"2012","unstructured":"Kubes P, Mehal WZ. Sterile inflammation in the liver. Gastroenterology. 2012;143(5):1158\u201372.","journal-title":"Gastroenterology"},{"issue":"5","key":"10082_CR26","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1002\/hep.30945","volume":"71","author":"W Zhong","year":"2020","unstructured":"Zhong W, et al. Paneth cell dysfunction mediates alcohol-related steatohepatitis through promoting bacterial translocation in mice: role of zinc deficiency. Hepatology. 2020;71(5):1575\u201391.","journal-title":"Hepatology"},{"issue":"2","key":"10082_CR27","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1002\/hep.30832","volume":"71","author":"S Lang","year":"2020","unstructured":"Lang S, et al. Intestinal fungal dysbiosis and systemic immune response to fungi in patients with alcoholic hepatitis. Hepatology. 2020;71(2):522\u201338.","journal-title":"Hepatology"},{"key":"10082_CR28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/hep.31178","volume":"72","author":"E Smirnova","year":"2020","unstructured":"Smirnova E, et al. Fecal microbiome distinguishes alcohol consumption from alcoholic hepatitis but does not discriminate disease severity. Hepatology. 2020;72:271.","journal-title":"Hepatology"},{"issue":"1","key":"10082_CR29","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.gastro.2014.10.042","volume":"148","author":"G Szabo","year":"2015","unstructured":"Szabo G. Gut-liver axis in alcoholic liver disease. Gastroenterology. 2015;148(1):30\u20136.","journal-title":"Gastroenterology"},{"issue":"5","key":"10082_CR30","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1053\/j.gastro.2009.01.056","volume":"136","author":"M Dominguez","year":"2009","unstructured":"Dominguez M, et al. Hepatic expression of CXC chemokines predicts portal hypertension and survival in patients with alcoholic hepatitis. Gastroenterology. 2009;136(5):1639\u201350.","journal-title":"Gastroenterology"},{"issue":"5","key":"10082_CR31","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1053\/j.gastro.2014.01.018","volume":"146","author":"J Altamirano","year":"2014","unstructured":"Altamirano J, et al. A histologic scoring system for prognosis of patients with alcoholic hepatitis. Gastroenterology. 2014;146(5):1231\u20139 (e1\u20136).","journal-title":"Gastroenterology"},{"issue":"4","key":"10082_CR32","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1002\/hep.30617","volume":"70","author":"B Saha","year":"2019","unstructured":"Saha B, et al. Biomarkers of macrophage activation and immune danger signals predict clinical outcomes in alcoholic hepatitis. Hepatology. 2019;70(4):1134\u201349.","journal-title":"Hepatology"},{"issue":"4","key":"10082_CR33","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1038\/nrgastro.2015.35","volume":"12","author":"A Louvet","year":"2015","unstructured":"Louvet A, Mathurin P. Alcoholic liver disease: mechanisms of injury and targeted treatment. Nat Rev Gastroenterol Hepatol. 2015;12(4):231\u201342.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"10082_CR34","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1038\/nprot.2013.032","volume":"8","author":"A Bertola","year":"2013","unstructured":"Bertola A, et al. Mouse model of chronic and binge ethanol feeding (the NIAAA model). Nat Protoc. 2013;8(3):627\u201337.","journal-title":"Nat Protoc"},{"issue":"1","key":"10082_CR35","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1038\/nrgastro.2017.116","volume":"15","author":"R Parker","year":"2018","unstructured":"Parker R, Kim SJ, Gao B. Alcohol, adipose tissue and liver disease: mechanistic links and clinical considerations. Nat Rev Gastroenterol Hepatol. 2018;15(1):50\u20139.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"5","key":"10082_CR36","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/hep.30525","volume":"69","author":"SJ Kim","year":"2019","unstructured":"Kim SJ, et al. Adipocyte death preferentially induces liver injury and inflammation through the activation of chemokine (C-C Motif) receptor 2-positive macrophages and lipolysis. Hepatology. 2019;69(5):1965\u201382.","journal-title":"Hepatology"},{"key":"10082_CR37","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1002\/hep.31041","volume":"72","author":"JH Lee","year":"2020","unstructured":"Lee JH, et al. Mitochondrial double-stranded RNA in exosome promotes interleukin-17 production through toll-like receptor 3 in alcoholic liver injury. Hepatology. 2020;72:609\u201325.","journal-title":"Hepatology"},{"issue":"4","key":"10082_CR38","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/hep.28988","volume":"65","author":"GK Michalopoulos","year":"2017","unstructured":"Michalopoulos GK. Hepatostat: Liver regeneration and normal liver tissue maintenance. Hepatology. 2017;65(4):1384\u201392.","journal-title":"Hepatology"},{"issue":"3","key":"10082_CR39","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/0016-5085(79)90017-9","volume":"77","author":"JR Wands","year":"1979","unstructured":"Wands JR, et al. Inhibition of hepatic regeneration in rats by acute and chronic ethanol intoxication. Gastroenterology. 1979;77(3):528\u201331.","journal-title":"Gastroenterology"},{"issue":"4","key":"10082_CR40","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jhep.2019.11.013","volume":"72","author":"X Xiang","year":"2020","unstructured":"Xiang X, et al. Interleukin-22 ameliorates acute-on-chronic liver failure by reprogramming impaired regeneration pathways in mice. J Hepatol. 2020;72(4):736\u201345.","journal-title":"J Hepatol"},{"issue":"4","key":"10082_CR41","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.alcohol.2007.04.008","volume":"41","author":"N Horiguchi","year":"2007","unstructured":"Horiguchi N, Ishac EJ, Gao B. Liver regeneration is suppressed in alcoholic cirrhosis: correlation with decreased STAT3 activation. Alcohol. 2007;41(4):271\u201380.","journal-title":"Alcohol"},{"issue":"12","key":"10082_CR42","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1136\/gutjnl-2014-308410","volume":"64","author":"L Dubuquoy","year":"2015","unstructured":"Dubuquoy L, et al. Progenitor cell expansion and impaired hepatocyte regeneration in explanted livers from alcoholic hepatitis. Gut. 2015;64(12):1949\u201360.","journal-title":"Gut"},{"issue":"6","key":"10082_CR43","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1002\/hep.25614","volume":"55","author":"P Sancho-Bru","year":"2012","unstructured":"Sancho-Bru P, et al. Liver progenitor cell markers correlate with liver damage and predict short-term mortality in patients with alcoholic hepatitis. Hepatology. 2012;55(6):1931\u201341.","journal-title":"Hepatology"},{"key":"10082_CR44","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1146\/annurev-immunol-032414-112123","volume":"33","author":"JA Dudakov","year":"2015","unstructured":"Dudakov JA, Hanash AM, van den Brink MR. Interleukin-22: immunobiology and pathology. Annu Rev Immunol. 2015;33:747\u201385.","journal-title":"Annu Rev Immunol"},{"issue":"7","key":"10082_CR45","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/s41423-018-0055-6","volume":"16","author":"B Gao","year":"2019","unstructured":"Gao B, Xiang X. Interleukin-22 from bench to bedside: a promising drug for epithelial repair. Cell Mol Immunol. 2019;16(7):666\u20137.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10082_CR46","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00281-009-0188-x","volume":"32","author":"K Wolk","year":"2010","unstructured":"Wolk K, et al. Biology of interleukin-22. Semin Immunopathol. 2010;32(1):17\u2013311.","journal-title":"Semin Immunopathol"},{"issue":"1","key":"10082_CR47","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/nrd4176","volume":"13","author":"R Sabat","year":"2014","unstructured":"Sabat R, Ouyang W, Wolk K. Therapeutic opportunities of the IL-22-IL-22R1 system. Nat Rev Drug Discov. 2014;13(1):21\u201338.","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"10082_CR48","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1016\/j.jhep.2016.02.004","volume":"64","author":"D Schmidt-Arras","year":"2016","unstructured":"Schmidt-Arras D, Rose-John S. IL-6 pathway in the liver: from physiopathology to therapy. J Hepatol. 2016;64(6):1403\u201315.","journal-title":"J Hepatol"},{"issue":"5","key":"10082_CR49","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1136\/gutjnl-2017-315284","volume":"67","author":"B Gao","year":"2018","unstructured":"Gao B, Ma J, Xiang X. MAIT cells: a novel therapeutic target for alcoholic liver disease? Gut. 2018;67(5):784\u20136.","journal-title":"Gut"},{"issue":"3","key":"10082_CR50","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/hep.29573","volume":"67","author":"Z Lu","year":"2018","unstructured":"Lu Z, et al. MicroRNA 15a\/16-1 suppresses aryl hydrocarbon receptor-dependent interleukin-22 secretion in CD4(+) T cells and contributes to immune-mediated organ injury. Hepatology. 2018;67(3):1027\u201340.","journal-title":"Hepatology"},{"issue":"5","key":"10082_CR51","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1002\/hep.20184","volume":"39","author":"S Radaeva","year":"2004","unstructured":"Radaeva S, et al. Interleukin 22 (IL-22) plays a protective role in T cell-mediated murine hepatitis: IL-22 is a survival factor for hepatocytes via STAT3 activation. Hepatology. 2004;39(5):1332\u201342.","journal-title":"Hepatology"},{"issue":"1","key":"10082_CR52","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1053\/j.gastro.2012.03.044","volume":"143","author":"D Feng","year":"2012","unstructured":"Feng D, et al. Interleukin-22 promotes proliferation of liver stem\/progenitor cells in mice and patients with chronic hepatitis B virus infection. Gastroenterology. 2012;143(1):188\u201398 (e7).","journal-title":"Gastroenterology"},{"issue":"3","key":"10082_CR53","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1002\/hep.25744","volume":"56","author":"X Kong","year":"2012","unstructured":"Kong X, et al. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology. 2012;56(3):1150\u20139.","journal-title":"Hepatology"},{"issue":"1","key":"10082_CR54","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/hep.24339","volume":"54","author":"O Park","year":"2011","unstructured":"Park O, et al. In vivo consequences of liver-specific interleukin-22 expression in mice: Implications for human liver disease progression. Hepatology. 2011;54(1):252\u201361.","journal-title":"Hepatology"},{"issue":"3","key":"10082_CR55","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1002\/hep4.1303","volume":"3","author":"K Schwarzkopf","year":"2019","unstructured":"Schwarzkopf K, et al. IL-22 and IL-22-binding protein are associated with development of and mortality from acute-on-chronic liver failure. Hepatol Commun. 2019;3(3):392\u2013405.","journal-title":"Hepatol Commun"},{"issue":"12","key":"10082_CR56","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.4049\/jimmunol.1700587","volume":"199","author":"D Kleinschmidt","year":"2017","unstructured":"Kleinschmidt D, et al. A protective function of IL-22BP in ischemia reperfusion and acetaminophen-induced liver injury. J Immunol. 2017;199(12):4078\u201390.","journal-title":"J Immunol"},{"issue":"1","key":"10082_CR57","first-page":"43","volume":"1","author":"H Pan","year":"2004","unstructured":"Pan H, et al. Hydrodynamic gene delivery of interleukin-22 protects the mouse liver from concanavalin A-, carbon tetrachloride-, and Fas ligand-induced injury via activation of STAT3. Cell Mol Immunol. 2004;1(1):43\u20139.","journal-title":"Cell Mol Immunol"},{"issue":"6","key":"10082_CR58","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/icb.2011.79","volume":"90","author":"X Xiang","year":"2012","unstructured":"Xiang X, et al. IL-22 and non-ELR-CXC chemokine expression in chronic hepatitis B virus-infected liver. Immunol Cell Biol. 2012;90(6):611\u20139.","journal-title":"Immunol Cell Biol"},{"issue":"1","key":"10082_CR59","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2015.02.004","volume":"63","author":"R Lai","year":"2015","unstructured":"Lai R, et al. Protective effect of Th22 cells and intrahepatic IL-22 in drug induced hepatocellular injury. J Hepatol. 2015;63(1):148\u201355.","journal-title":"J Hepatol"},{"issue":"3","key":"10082_CR60","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1111\/jgh.13537","volume":"32","author":"R Mo","year":"2017","unstructured":"Mo R, et al. Persistently elevated circulating Th22 reversely correlates with prognosis in HBV-related acute-on-chronic liver failure. J Gastroenterol Hepatol. 2017;32(3):677\u201386.","journal-title":"J Gastroenterol Hepatol"},{"issue":"3","key":"10082_CR61","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1128\/IAI.01268-15","volume":"84","author":"M Zheng","year":"2016","unstructured":"Zheng M, et al. Therapeutic role of interleukin 22 in experimental intra-abdominal klebsiella pneumoniae infection in mice. Infect Immun. 2016;84(3):782\u20139.","journal-title":"Infect Immun"},{"issue":"4","key":"10082_CR62","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1002\/hep.23837","volume":"52","author":"SH Ki","year":"2010","unstructured":"Ki SH, et al. Interleukin-22 treatment ameliorates alcoholic liver injury in a murine model of chronic-binge ethanol feeding: role of signal transducer and activator of transcription 3. Hepatology. 2010;52(4):1291\u2013300.","journal-title":"Hepatology"},{"issue":"4","key":"10082_CR63","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.ajpath.2012.12.010","volume":"182","author":"P Scheiermann","year":"2013","unstructured":"Scheiermann P, et al. Application of interleukin-22 mediates protection in experimental acetaminophen-induced acute liver injury. Am J Pathol. 2013;182(4):1107\u201313.","journal-title":"Am J Pathol"},{"issue":"5","key":"10082_CR64","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.4049\/jimmunol.1400588","volume":"193","author":"D Feng","year":"2014","unstructured":"Feng D, et al. Acute and chronic effects of IL-22 on acetaminophen-induced liver injury. J Immunol. 2014;193(5):2512\u20138.","journal-title":"J Immunol"},{"issue":"15","key":"10082_CR65","doi-asserted-by":"crossref","first-page":"4170","DOI":"10.7150\/thno.25798","volume":"8","author":"R Mo","year":"2018","unstructured":"Mo R, et al. Enhanced autophagy contributes to protective effects of IL-22 against acetaminophen-induced liver injury. Theranostics. 2018;8(15):4170\u201380.","journal-title":"Theranostics"},{"issue":"3","key":"10082_CR66","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/intimm\/dxt049","volume":"26","author":"H Abe","year":"2014","unstructured":"Abe H, et al. Aryl hydrocarbon receptor plays protective roles in ConA-induced hepatic injury by both suppressing IFN-gamma expression and inducing IL-22. Int Immunol. 2014;26(3):129\u201337.","journal-title":"Int Immunol"},{"key":"10082_CR67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13578-015-0015-0","volume":"5","author":"O Park","year":"2015","unstructured":"Park O, et al. Biologically active, high levels of interleukin-22 inhibit hepatic gluconeogenesis but do not affect obesity and its metabolic consequences. Cell Biosci. 2015;5:25.","journal-title":"Cell Biosci"},{"issue":"2","key":"10082_CR68","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.jhep.2010.03.004","volume":"53","author":"L Yang","year":"2010","unstructured":"Yang L, et al. Amelioration of high fat diet induced liver lipogenesis and hepatic steatosis by interleukin-22. J Hepatol. 2010;53(2):339\u201347.","journal-title":"J Hepatol"},{"key":"10082_CR69","doi-asserted-by":"crossref","first-page":"5879","DOI":"10.7150\/thno.43894","volume":"10","author":"W Chen","year":"2020","unstructured":"Chen W, et al. Interleukin-22 drives a metabolic adaptive reprogramming to maintain mitochondrial fitness and treat liver injury. Theranostics. 2020;10:5879\u201394.","journal-title":"Theranostics"},{"key":"10082_CR70","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/hep.31031","volume":"72","author":"S Hwang","year":"2020","unstructured":"Hwang S, et al. Interleukin-22 ameliorates neutrophil-driven nonalcoholic steatohepatitis through multiple targets. Hepatology. 2020;72:412\u201329.","journal-title":"Hepatology."},{"issue":"4","key":"10082_CR71","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1055\/s-0037-1608788","volume":"37","author":"G Szabo","year":"2017","unstructured":"Szabo G. Clinical trial design for alcoholic hepatitis. Semin Liver Dis. 2017;37(4):332\u201342.","journal-title":"Semin Liver Dis"},{"issue":"Suppl 2","key":"10082_CR72","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s12072-014-9516-x","volume":"8","author":"M Xu","year":"2014","unstructured":"Xu M, et al. New drug targets for alcoholic liver disease. Hepatol Int. 2014;8(Suppl 2):475\u201380.","journal-title":"Hepatol Int"},{"issue":"2","key":"10082_CR73","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2018.10.026","volume":"70","author":"AK Singal","year":"2019","unstructured":"Singal AK, Shah VH. Current trials and novel therapeutic targets for alcoholic hepatitis. J Hepatol. 2019;70(2):305\u201313.","journal-title":"J Hepatol"},{"key":"10082_CR74","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/hep.31046","volume":"72","author":"JP Arab","year":"2020","unstructured":"Arab JP, et al. An open label, dose escalation study to assess the safety and efficacy of IL-22 agonist F-652 in patients with alcoholic hepatitis. Hepatology. 2020;72:441\u201353.","journal-title":"Hepatology"},{"issue":"3","key":"10082_CR75","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1002\/hep.30516","volume":"70","author":"SM Shasthry","year":"2019","unstructured":"Shasthry SM, et al. Efficacy of granulocyte colony-stimulating factor in the management of steroid-nonresponsive severe alcoholic hepatitis: a double-blind randomized controlled trial. Hepatology. 2019;70(3):802\u201311.","journal-title":"Hepatology"},{"issue":"5","key":"10082_CR76","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41423-018-0029-8","volume":"16","author":"KY Tang","year":"2019","unstructured":"Tang KY, et al. Safety, pharmacokinetics, and biomarkers of F-652, a recombinant human interleukin-22 dimer, in healthy subjects. Cell Mol Immunol. 2019;16(5):473\u201382.","journal-title":"Cell Mol Immunol"},{"issue":"1","key":"10082_CR77","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/cpt.1164","volume":"105","author":"ME Rothenberg","year":"2019","unstructured":"Rothenberg ME, et al. Randomized phase I healthy volunteer study of UTTR1147A (IL-22Fc): a potential therapy for epithelial injury. Clin Pharmacol Ther. 2019;105(1):177\u201389.","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10082_CR78","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1002\/hep.24486","volume":"54","author":"R Jiang","year":"2011","unstructured":"Jiang R, et al. Interleukin-22 promotes human hepatocellular carcinoma by activation of STAT3. Hepatology. 2011;54(3):900\u20139.","journal-title":"Hepatology"},{"issue":"4","key":"10082_CR79","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.immuni.2007.07.023","volume":"27","author":"LA Zenewicz","year":"2007","unstructured":"Zenewicz LA, et al. Interleukin-22 but not interleukin-17 provides protection to hepatocytes during acute liver inflammation. Immunity. 2007;27(4):647\u201359.","journal-title":"Immunity"},{"issue":"8","key":"10082_CR80","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1136\/gutjnl-2018-317232","volume":"68","author":"T Hendrikx","year":"2019","unstructured":"Hendrikx T, et al. Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice. Gut. 2019;68(8):1504\u201315.","journal-title":"Gut"},{"issue":"7521","key":"10082_CR81","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature13564","volume":"514","author":"X Wang","year":"2014","unstructured":"Wang X, et al. Interleukin-22 alleviates metabolic disorders and restores mucosal immunity in diabetes. Nature. 2014;514(7521):237\u201341.","journal-title":"Nature"},{"key":"10082_CR82","doi-asserted-by":"crossref","first-page":"36436","DOI":"10.1038\/srep36436","volume":"6","author":"BL Hu","year":"2016","unstructured":"Hu BL, et al. Interleukin-22 ameliorates liver fibrosis through miR-200a\/beta-catenin. Sci Rep. 2016;6:36436.","journal-title":"Sci Rep"},{"issue":"1","key":"10082_CR83","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jhep.2015.08.023","volume":"64","author":"E Eggenhofer","year":"2016","unstructured":"Eggenhofer E, et al. RORgammat(+) IL-22-producing NKp46(+) cells protect from hepatic ischemia reperfusion injury in mice. J Hepatol. 2016;64(1):128\u201334.","journal-title":"J Hepatol"}],"container-title":["Hepatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10082-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12072-020-10082-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12072-020-10082-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,4]],"date-time":"2021-09-04T23:58:37Z","timestamp":1630799917000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12072-020-10082-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":83,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,9]]}},"alternative-id":["10082"],"URL":"https:\/\/doi.org\/10.1007\/s12072-020-10082-6","relation":{},"ISSN":["1936-0533","1936-0541"],"issn-type":[{"value":"1936-0533","type":"print"},{"value":"1936-0541","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"11 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This\u00a0article\u00a0does not contain any studies with\u00a0human or animal subjects.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human and animal participants"}}]}}